Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

BACKGROUND: MEDI9197 is an intratumorally administered toll-like receptor 7 and 8 agonist. In mice, MEDI9197 modulated antitumor immune responses, inhibited tumor growth and increased survival. This first-time-in-human, phase 1 study evaluated MEDI9197 with or without the programmed cell death ligan...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Immunother Cancer
المؤلفون الرئيسيون: Siu, Lillian, Brody, Joshua, Gupta, Shilpa, Marabelle, Aurélien, Jimeno, Antonio, Munster, Pamela, Grilley-Olson, Juneko, Rook, Alain H, Hollebecque, Antoine, Wong, Rebecca K S, Welsh, James W, Wu, Yuling, Morehouse, Christopher, Hamid, Oday, Walcott, Farzana, Cooper, Zachary A, Kumar, Rakesh, Ferté, Charles, Hong, David S
التنسيق: Artigo
اللغة:Inglês
منشور في: BMJ Publishing Group 2020
الموضوعات:
Oncolytic and Local Immunotherapy
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549442/
https://ncbi.nlm.nih.gov/pubmed/33037117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001095
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة